866-484-8870
|
Expand search form
Menu
GTC establishes east coast laboratory
Anthology Dx in Partnership with Hackensack Meridian Health
Learn More
Reduce Cancer Disparity
GTC offers Molecular Profiling to Minority Patients without Adequate Insurance Coverage
Learn More - Donate
How to Order
a Test
Req Forms and User Guides
Access Requisition
Reduce Cancer Disparity
GTC offers Molecular Profiling to Minority Patients without Adequate Insurance Coverage
Learn More - Donate
GTC establishes east coast laboratory
Anthology Dx in Partnership with Hackensack Meridian Health
Learn More
How to Order
a Test
Req Forms and User Guides
Access Requisition
Innovation in Next-Gen Sequencing
Making Genomic Testing Available and Affordable for Everyone
Learn More About GTC
Record Breaking TAT
Receive Your NGS Results in 7 Days or Less
Learn How to Reduce Your TTI
Previous
Next
Upcoming CME Webinar
Upcoming CME Webinar
Please join us Tuesday, March 30th at 4-5 PM PST for a continuing medical education (CME) webinar.
 
Dr. Maher Albitar and Dr. Andre Goy will be presenting From Genomics to Cancer: Complexity of Diffuse Large B-Cell Lymphoma and Clinical Implication.

Register Now

 

Course Description:

From Genomics to Cancer: Methods and Approaches for Analyzing and Interpreting DNA and RNA Next-Generation Sequencing Data 

This course introduces the principles and various approaches of Next Generation Sequencing (NGS) and demonstrates how NGS data can be used to detect single nucleotide variation (SNV) and indels, measure expression, evaluate copy number variation (CNV), distinguish between germline and somatic abnormalities, then interpret the data in a clinical setting and make recommendation for patients management and therapeutic approaches.

 The course also introduces key concepts in computing, software and algorithms that can be used for analyzing data for reaching clinical decisions. 

Objectives:

At the conclusion of this activity, the participant should be able to:

1. Interpret test results from solid and hematologic cancers utilizing next generation sequencing; 

2. Utilize genomic interpretation software to determine genomic alterations impacting diagnosis, prognosis and response to therapy.

Target Audience:

Pathologists, Hematologists, Oncologists, Surgical Oncologists and Pathology Fellows

 

Committed to driving the field of oncology diagnostics forward

Physicians
Patients

Answers in
7 days or less

Results in 7 days for DNA, 10 days for RNA tests

Evolving oncology diagnosis, prognosis and precision medicine

hp-core-technology-sequencing-web-graphic

Don’t accept partial results.

Cancer is a complex disease requiring comprehensive answers. Only a comprehensive answer will allow medical professionals to make the highest quality care decisions for their patients.  At GTC we analyze both DNA and RNA which gives the best possible answers based on our current knowledge.

GTC Provides Comprehensive Answers

Learn More
0
Detected Genes

Both solid tumors (lung, colon, breast, etc) and hematologic malignancies (leukemia, multiple myeloma, etc) have molecular profiling tests available.

All major types of cancer have molecular testing that can be performed on them but the sample requirements will be different.

Record Breaking Turn Around Time
7 Days or Less
Extremely Low QNS Rate
Lass than 1% 1%
  • In the case of solid tumors some form of biopsy will need to take place or a blood sample provided. 
  • For hematologic malignancies a bone marrow sample is most common but a blood sample may be adequate

Reduce your TTI

Test to Treatment Initialization
We are committed to serve patients and Doctors quickly

Record Breaking TAT*

Results in 5 to 7 days
We promised to provide reports in 7 days or less. Actually, we do better than that!
(*maximum 10 days for RNA results)
Learn More

Revolutionary Cooperation

A new way to internalize or outsource
your genomic profiling for cancer

Two ways to work together

You can cooperate Genomic Testing Cooperative by:
- Outsource Testing
- Internalize Testing
Learn More
gts AI

Machine/Deep Learning Meets Next Generation Sequencing

Genomic Testing Cooperative is creating a new kind of disruptive business model. We utilize advanced next-generation sequencing techniques and AI to offer the most innovative testing to our customers. Our co-op allows customers to select a level of service that suits their oncology testing requirements including:

1. An in-house genomics lab managed by GTC
2. Cooperative Associate
3. Client

Genomic testing is expensive and risky for smaller labs because of its complexity and rapidly changing information. Competing with larger labs is challenging to get scale for profitable operations and will face different billing challenges than routine tests.


GTC alleviates those risks and challenges for our customers handling innovation, medical oversight, operations, and billing.

GTC has created a co-op model to reduce sales, operations, and service costs – the biggest impediment to profitability by sharing resources. We have a level of membership that works for the smallest labs up to the biggest reference labs.


To learn more reach out for a capabilities presentation.

Most labs work on a basis where a lab sends a sample and the lab bills either the hospital or the patient. The relationship is purely transactional.

 

GTC allows members to join, share resources, share knowledge, have a voice in GTC, and collaborate in a community environment. The Co-op model produces big data for AI analysis creating value for hospitals, research, drug development, and other involved in cancer care.

Cooperatively we can all work together to improve community access to comprehensive genomic profiling and advance scientific discovery

GTC works with laboratories, hospitals, pathologists, oncologists, and other medical professionals to improve access to cutting edge technology at an affordable price by sharing resources and expertise.

 

Gain access to advanced technology, molecular expertise, and a pipeline for innovation and development of new tests.

 

GTC utilizes technology innovations that integrate artificial intelligence and proprietary algorithms within our informatics tools.  These tools enable faster turnaround times of results, comprehensive reporting including targeted and immunotherapy recommendations and clinical trial options.

 

Learn more about the GTC Co-Op model

Learn More

State-of-the-Art Innovation

Machine/Deep learning meets next generation sequencing

NGS

Next generation sequencing DNA/RNA testing

Genomic sequencing revolutionary methods never used before. Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs being approved regularly.

Co-Op

We work together to achieve more

A cooperation model of bringing new solutions. Simply put a Co-Op means we all work together as a team to make things better. In the case of the Genomic Testing Cooperative it means that our lab works with other labs, physicians and patients to improve the communities access to cutting edge healthcare.

AI Machine Learning

Bringing computer science to laboratories

Our AI helps us sort through curate large sets of data so we can quickly make sense of genomic alterations and assess their impact on a patient prognosis, diagnosis and help predict their response to therapy. We use machine learning to review these alterations and track their frequency.

State-of-the-Art Innovation

Machine/deep Learning meets Next Generation Sequencing

NGS

Next generation sequencing DNA/RNA testing

Genomic sequencing revolutionary methods never used before. Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs being approved regularly.

Co-Op

We work together to achieve more​

A Cooperation Model of Bringing new solutions. Simply put a co-op means we all work together as a team to make things better. In the case of the Genomic Testing Cooperative it means that our lab works with other labs, physicians and patients to improve the communities access to cutting edge healthcare.

AI Machine Learning

Bringing computer science to laboratories

Our AI helps us sort through curate large sets of data so we can quickly make sense of genomic alterations and assess their impact on a patient prognosis, diagnosis and help predict their response to therapy. We use machine learning to review these alterations and track their frequency.

Palmetto covers two NGS tests from GTC

Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms.

The Medicare Administrative Contractor Palmetto GBA (MolDx®) has finalized its review and has established coverage for two Genomic Testing Cooperative (GTC) hematology profiles:  GTC-Hematology (177 gene DNA profiling) and GTC-Hematology Plus (177 gene DNA and 1408 gene RNA profiling).

The two Comprehensive Genomic Profile (CGP) tests are designed to help Pathologists and Hematologists/Oncologists in establishing the precise diagnosis, prognosis and determine therapy in hematologic neoplasms.  

The GTC Hematology test (177 gene DNA Profile) can be performed on cell-free DNA (cf-DNA) from peripheral blood samples representing the first Palmetto GBA covered liquid biopsy for hematology. A liquid biopsy for suspected hematologic neoplasms or monitoring patients with hematologic neoplasms can be highly useful and practical as a replacement to the painful bone marrow biopsy, which can be a deterrent for some patients. 

READ MORE

Or Contact us today at 949-540-9421 to order and learn more about our NGS offering.

Get Results in 7 days.

Liquid biopsy

 

Pain free

Non-Invasive

Fast

Accurate

HEMATOLOGY PROFILE TEST
HEMATOLOGY PROFILE PLUS
LIQUID BIOPSY HEMATOLOGY PROFILE

Dr. Albitar Explains All the Competitive Advantages of GTC

Α detailed interview

Play Video

NGS is Enabling Medical Breakthroughs

Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs with being approved regularly. However, it has previously been cost prohibitive with many insurance companies not covering testing. The data sets it produced were also hard to interpret and understand due to their size, complexity and lack of historical data.

We have now reached a time where we can utilize genomic testing in a cost-effective matter. The tools are now available to make sense of the complex data. There is a large database of samples to look at and compare. In essence, we are at the tipping point of a deep understanding of cancer which we have never had before in human history and are making therapies that have the potential to cure the disease.

Revolutionary
Methods

GTC Advanced Genomic Testing

Learn More

For Patients.

Thank you for taking the time to read this page.

We understand right now you’re likely reading this because you have cancer
or you know someone who does and are seeking answers.

Cancer is a genomic disease and understanding what is happening at a genomic level helps medical professionals provide better care.

NON-INVASIVE LIQUID BIOPSY
WHY TESTING MATTERS
WHY TIME MATTERS
gtc for patients
Genomic Testing Cooperative Lab
Genomic Testing Cooperative Lab

Don’t Miss Another Update

Get all the critical news and events sent straight to your inbox.

Don’t Miss Another Update

Get all the critical news and events sent straight to your inbox.



Contact Us.

Let’s talk

Contact Info

  • 175 Technology Dr, Suite 100 Irvine, CA 92618
  • (949) 540-9421
  • gtc@genomictestingcooperative.com